Astellas muscle deal pumps new funding into Cytokinetics
This article was originally published in Scrip
The US firm Cytokinetics will receive at least $40 million in upfront and reimbursement payments for R&D activities over the first two years of a new collaboration with Astellas for skeletal muscle activators (SMAs).
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.